Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation

Citation
Jp. Shannon et al., Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation, J PEPT RES, 58(2), 2001, pp. 140-150
Citations number
54
Categorie Soggetti
Biochemistry & Biophysics
Journal title
JOURNAL OF PEPTIDE RESEARCH
ISSN journal
1397002X → ACNP
Volume
58
Issue
2
Year of publication
2001
Pages
140 - 150
Database
ISI
SICI code
1397-002X(200108)58:2<140:NCPIIA>2.0.ZU;2-T
Abstract
Leukocyte adherence mediated by intercellular adhesion molecule-1 (ICAM-1) binding to leukocyte function-associated antigen (LFA-1) is required for pr oper inflammatory and immune function. Inhibition of ICAM-1\LFA-1 binding u sing monoclonal antibodies (mAb) has been shown to be efficacious at inhibi ting lymphoma metastasis as well as leukocyte emigration into tissue in a n umber of inflammatory diseases such as ischemia-reperfusion injury, septic shock and rheumatoid arthritis. In this report, we describe the development and characterization of a small peptide antagonist of ICAM-1-dependent cel l aggregation. By using repeated selection of a cyclic nonapeptide phage di splay library on purified ICAM-1, we identified phage that were competitive ly eluted with anti-ICAM-1 mAb. The peptide sequences were determined by nu cleotide sequencing, and the peptide sequence (C*LLRMRSIC*) (IP01) that occ urred most frequently was chosen for further study. Phage expressing this p eptide sequence specifically bound ICAM-1 over a range of 5x10(6) to 1x10(8 ) phage/muL. A cyclic IP01 peptide, linear IP01 peptide, a cyclic nonapepti de with a scrambled IP01 sequence, and a random, cyclic nonapeptide were sy nthesized. The cyclic and linear IP01 peptides were able to inhibit ICAM-1- mediated cell aggregation at a concentration of 1 mm, whereas the random an d scrambled peptide sequences did not alter aggregation. Cyclic IP01 had a half-maximal inhibitory concentration of approximate to 970 muM. Cyclic IP0 1 did not inhibit cellular aggregation that was dependent on ICAM-2 or ICAM -3. Alanine substitutions in the cyclic IP01 identified at least four amino acids necessary for inhibition of ICAM-1 dependent cell aggregation; leuci ne 2, leucine 3, methionine 5, and arginine 6. Finally, we showed that cycl ic IP01 can inhibit firm adhesion of neutrophils to endothelium, a critical event in inflammatory diseases, in an assay that recapitulates physiologic flow conditions. Homology of IP01 with the primary amino acid sequences of the alpha or beta subunit of LFA-1 was not identified. Thus, we identified a unique molecule that inhibits ICAM-1 dependent cell adhesion, but is not related to the primary sequence of the ICAM-1 ligand LFA-1. Due to the sma ll size and ability to block cell-cell adhesion, IP01 may serve as a useful tool for study of ICAM-1 and LFA-1 biology as well as for the development of small molecule therapeutics.